



PRESS RELEASE

DNAVISION STRENGTHENS ITS SERVICES IN PHARMACOGENOMICS by PROVIDING NEW MICRORNA ASSAYS

Brussels, June 2nd 2005 – DNA Vision S.A. announced today that it has developed and validated **MicroRNAs quantification assays**. MicroRNAs are untranslated RNAs which regulate mRNA translation without inducing mRNA degradation. **DNA Vision** has validated a high throughput low cost method to quantify the expression of MicroRNAs from classical total RNA extraction without genomic DNA interferences. More than **150 human MicroRNAs** and more than **100 mouse MicroRNAs** have been validated using as little as 15 µg of total RNA. This method assumes accurate and sensitive MicroRNAs expression profiling to identify specific MicroRNAs signatures associated with tissues, biological process or diseases.

"The discovery of MicroRNAs has added a new dimension to the understanding of complex gene regulatory networks and their relationship to disease. By providing the first high throughput quantitative method, we are able to give more information about gene expression analysis", says JF Laes, PhD, Scientific Advisor for DNA Vision SA.

About DNA Vision SA.

DNA Vision is a leading provider of applied pharmacogenetic & pharmacogenomic services. DNA Vision offers the powerful combination of different technologies in expression profiling and SNP genotyping in a high quality environment. More information on DNA Vision' service portfolio can be found on www.dnavision.be

Further information:

Jean-Pol Detiffe, CEO
DNA Vision S.A.
Tel. +32 71 378 527
Fax. +32 71 378 501
jp.detiffe@dnavision.be
www.dnavision.be